Search: WFRF:(Walter Susanna) >
ReFerm®: a postbiot...
-
Biskou, OlgaLinköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten
(author)
ReFerm®: a postbiotic fermented oat gruel composition is reducing mast cell degranulation in the colon of patients with irritable bowel syndrome
- Article/chapterEnglish2024
Publisher, publication year, extent ...
-
FRONTIERS MEDIA SA,2024
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-206407
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-206407URI
-
https://doi.org/10.3389/fmed.2024.1408623DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Linkpings Universitet10.13039/501100003945; Nordic Rebalance
-
Background: Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder that affects similar to 4% of the global population. ReFerm((R)) is a postbiotic product derived from oat gruel fermented with Lactobacillus plantarum 299v, and it has been shown to have beneficial effects on intestinal permeability in patients with IBS. In this study, we investigated the effects of ReFerm((R)) on regulators of intestinal permeability, namely mast cells and enteric glial cells. Materials and methods: A total of 30 patients with moderate to severe IBS were treated with an enema containing ReFerm((R)) or a placebo twice daily. The patients underwent sigmoidoscopy with biopsies obtained from the distal colon at baseline and after 14 days of treatment. These biopsies were processed in two ways: some were fixed, embedded in paraffin, sectioned, and stained for mast cells and enteric glial cells; others were cryopreserved, lysed, and subjected to Western blotting to analyze the same markers. Results: Treatment with ReFerm((R)), but not the placebo, significantly reduced mast cell tryptase protein levels in the biopsy lysates. Although the number of mast cells remained unchanged in colonic biopsies, ReFerm((R)) treatment significantly reduced mast cell degranulation, a result not observed in the placebo group. Neither ReFerm((R)) or placebo treatment had an impact on total protein levels or the number of enteric glial cells in the biopsies. Conclusion: ReFerm((R)) treatment significantly reduced both total mast cell tryptase levels and the degranulation of mast cells in colonic biopsies from patients with IBS, suggesting a decrease in mast cell activity as a potential mechanism underlying the beneficial effects of ReFerm((R)). However, further research is required to assess the molecular mechanisms through which ReFerm((R)) operates in the colons of patients with IBS.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Walter, SusannaLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)suswa35
(author)
-
Israelsen, HansNord Rebalance AS, Denmark
(author)
-
Winberg, Martin E.Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten(Swepub:liu)marwi07
(author)
-
Bednarska, OlgaLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)olgbe12
(author)
-
Keita, Åsa V.Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten(Swepub:liu)asave24
(author)
-
Linköpings universitetAvdelningen för kirurgi, ortopedi och onkologi
(creator_code:org_t)
Related titles
-
In:Frontiers in Medicine: FRONTIERS MEDIA SA112296-858X
Internet link
Find in a library
To the university's database